Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Evaluation of an injection depot formulation of buprenorphine: placebo comparison (2004)
    Oxford, UK : Blackwell Science Ltd
    Addiction 99 (2004), S. 0 
    Details
    ISSN: 1360-0443
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine , Psychology
    Notes: Aims  Buprenorphine is a mu-opioid partial agonist that is marketed in a sublingual formulation as a treatment for opioid dependence. A microcapsule depot sustained-release formulation has been developed which may offer effective treatment  of  opioid  dependence  while  also  minimizing  risks  of  illicit  diversion or patient non-compliance. The present study examined the efficacy of depot buprenorphine in suppressing the opioid withdrawal syndrome and in attenuating the effects of exogenous opioid challenge.Design  A placebo-controlled, double-blind, randomized trial.Setting  A closed residential research facility.Participants  A total of 15 opioid-dependent participants were enrolled into the 6-week study.Intervention  Fifteen participants were randomized to receive a single subcutaneous depot injection containing buprenorphine (58 mg) or placebo. Two participants, both of whom received placebo, terminated participation after depot administration. Thirteen participants (six buprenorphine, seven placebo) completed the 6-week study and were assessed throughout the study for signs and symptoms of opioid withdrawal and for response to weekly subcutaneous challenges with 3 mg hydromorphone.Measurement  Subjective, physiological and observer-rated indices of opioid withdrawal and opioid agonist effects.Findings  Depot buprenorphine provided more effective relief from opioid withdrawal than placebo, as evidenced by significantly fewer buprenorphine participants requiring supplemental medications for withdrawal suppression after depot administration compared to participants receiving placebo. In the weekly hydromorphone challenge sessions, depot buprenorphine significantly reduced opioid response on measures of subjective effects and pupillary diameter.Conclusions  Results from this double-blind, placebo-controlled study indicate that depot buprenorphine is effective in providing both withdrawal suppression and opioid blockade. Future studies examining additional doses and repeated dosing regimens with depot buprenorphine are warranted.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1360-0443.2004.00834.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Hydromorphone effects on human conversational speech (1984)
    Springer
    Psychopharmacology 84 (1984), S. 402-404 
    Details
    ISSN: 1432-2072
    Keywords: Hydromorphone ; Opiate drugs ; Human speech ; Behavioral effects ; Subjective effects ; Drug reinforcement ; Drug abusers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The present study provides an objective assessment of the increased talkativeness associated with acute opiate drug administration. Speech of five methadone-maintenance subjects was recorded continuously for 1 h following the injection of 0, 10, 14, or 18 mg hydromorphone. Dose-related increases in subjects' speech were observed, while no systematic changes were seen in speech of an undrugged partner. Dose-related increases were also obtained on an adjective checklist measuring characteristic opiate signs and symptoms. The relationship between behavioral, subjective, and reinforcing drug effects is discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00555221
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Relative abuse liability of diazepam and oxazepam: Behavioral and subjective dose effects (1984)
    Springer
    Psychopharmacology 84 (1984), S. 147-154 
    Details
    ISSN: 1432-2072
    Keywords: Diazepam ; Oxazepam ; Subjective effects ; Psychomotor effects ; Relative potency ; Time course ; Tolerance ; Abuse liability ; Drug abuse ; Humans
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The effects of diazepam (10–160 mg) and oxazepam (30–480 mg) were studied in volunteers with histories of drug abuse. Oral doses were administered every third day under double-blind and counterbalanced conditions. Dose-effects with area under the time-action curve data (AUC) showed diazepam to be 2.6-5.7-times more potent than oxazepam on various psychomotor, cognitive, staff-rated, and subjective measures. Comparison of relative potencies showed diazepam to be relatively more potent in producing ‘liking’ than in producing psychomotor and cognitive effects. Diazepam produced greater peak effects than oxazepam on a number of staff- and subject-rated measures, including liking. Onset of effect was more rapid and time to maximal effect was shorter (1–2 h versus 4–12 h) with diazepam than oxazepam, while time to offset of effect was similar for the two drugs. Diazepam was categorized as producing barbiturate-like subjective effects (38.3%) more frequently than was oxazepam (13.8%), while oxazepam was identified as placebo more often than diazepam. Repeated administration of 160 mg diazepam and 480 mg oxazepam showed that AUC liking was greater for diazepam than oxazepam and that tolerance to psychomotor and cognitive effects occurred with oxazepam but not diazepam. This study suggests that diazepam may have a higher abuse liability than oxazepam.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00427437
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Buprenorphine and naloxone alone and in combination in opioid-dependent humans (1988)
    Springer
    Psychopharmacology 94 (1988), S. 484-490 
    Details
    ISSN: 1432-2072
    Keywords: Buprenorphine ; Hydromorphone ; Naloxone ; Methadone ; Precipitated opioid withdrawal
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Subjective, physiological and behavioral effects of subcutaneously administered hydromorphone (6 mg), naloxone (0.2 mg), buprenorphine (0.2 and 0.3 mg), and two buprenorphine-naloxone combinations (buprenorphine 0.2 mg plus naloxone 0.2 mg and buprenorphine 0.3 mg plus naloxone 0.2 mg) were assessed under double-blind conditions in six opioid-dependent volunteers. Physiologic measures and subject- and observer-rated behavioral responses were measured before dosing and for 120 min after drug administration. Hydromorphone decreased pupil diameter and respiration, increased blood pressure and increased scores on subjective measures indicating opioid-like effects. Buprenorphine given alone had no significant effect on any variable measured. Naloxone given alone produced opioid abstinence-like effects which were measurable on subject- and observer-rated behavioral measures and physiological measures. Buprenorphine in combination with naloxone somewhat attenuated the naloxone-precipitated withdrawal response. Overall, the naloxone-buprenorphine combinations produced effects which were qualitatively similar to the effects of naloxone alone, suggesting a low potential for abuse of the combination product by opioid-dependent individuals.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00212842
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    The effects of buprenorphine in buprenorphine-maintained volunteers (1997)
    Springer
    Psychopharmacology 129 (1997), S. 329-338 
    Details
    ISSN: 1432-2072
    Keywords: Key words Abuse liability testing ; Agonist-antagonist ; Buprenorphine ; Hydromorphone ; Opioid dependence
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Buprenorphine is a mu opioid partial agonist currently used as an analgesic, and being developed for the treatment of opioid dependence. The purpose of this study was to determine the abuse liability of parenteral buprenorphine in volunteers maintained on daily sublingual (SL) buprenorphine (8 mg). In a residential laboratory, eight volunteers underwent pharmacologic challenges two times per week. Medication challenges were 16 h after the daily dose of buprenorphine, and consisted of double-blind IM injections of buprenorphine (4, 8, 16 mg), the prototypic mu opioid agonist hydromorphone (9 and 18 mg), or saline. Assessments consisted of physiologic monitoring, subjects’ self-reports, and a trained observer’s ratings of drug effects, and were collected for 0.5 h before and 2.0 h following injection. Supplemental doses of IM buprenorphine produced opioid agonist-like effects, indicating some abuse potential of parenteral buprenorphine in buprenorphine-maintained patients. There was incomplete cross-tolerance to the effects of hydromorphone, suggesting that higher maintenance doses of buprenorphine may be needed to maximize clinical efficacy. However, there was a lack of graded dose-effects for hydromorphone, suggesting that buprenorphine’s combination of partial agonist effects and high affinity for opioid receptors may limit the magnitude of effects of supplemental full agonists. Finally, participants tolerated cumulative doses of maintenance buprenorphine plus challenge buprenorphine without adverse effects, suggesting higher doses of buprenorphine can be safely administered to opioid dependent patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002130050199
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users (1994)
    Springer
    Psychopharmacology 116 (1994), S. 401-406 
    Details
    ISSN: 1432-2072
    Keywords: Buprenorphine ; Cocaine ; Heroin ; Methadone ; Opioids
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract This study compared the efficacy of buprenorphine to methadone for decreasing cocaine use in patients with combined opioid and cocaine use. Participants (n=51) were enrolled in a 26-week treatment program and randomly assigned to either buprenorphine or methadone. Dosing was double-blind and double-dummy. Patients were stabilized on either 8 mg sublingual buprenorphine or 50 mg oral methadone, with dose increases given in response to continued illicit cocaine use or opioid use through week 16 of treatment. Maximum doses possible were 16 mg buprenorphine and 90 mg methadone. Average doses achieved were 11.2 mg buprenorphine and 66.6 mg methadone; 49% of the patients received the maximum doses possible. Urine samples were collected three times per week, and there was no significant difference in the rate of cocaine positive urines for the intent-to-treat sample (69% for buprenorphine versus 63% for methadone). For patients who remained in treatment through the flexible dosing period (n=28), there were significant decreases in cocaine positive urines over time (P〈0.01), but no significant differences between groups or group × time effects. Buprenorphine and methadone were equally effective on measures of treatment retention, urine results for opioids, and compliance with attendance and counseling. These results demonstrate no selective efficacy of either buprenorphine or methadone in attenuating cocaine use in this population, but do provide further support for the equivalent efficacy of buprenorphine and methadone in the treatment of opioid dependence.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02247469
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    The token economy as a research method in alcoholism (1971)
    Springer
    Psychiatric quarterly 45 (1971), S. 574-581 
    Details
    ISSN: 1573-6709
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract “Frequently such reinforcers as medical care, custodial services, disability payments, and personal attention are denied the alcoholic in the early stages of his career, and are made contingent on his demonstrating advanced or irreversible physical and psychological deterioration. ... Whether clues toward [strategies for early intervention] may evolve from the laboratory will constitute the ultimate test of the token economy as a research tool in alcoholism.”
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01563218
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...